arrow
Back
S

Se Hoon Park

Samsung Medical Center and Sungkyunkwan University School of Medicine

72H-index
672Paper Count
3.0WCitation Count
Published Papers 170
Publication Date
Toxicity-related immunotherapy discontinuation and outcome in patients with advanced renal cell carcinoma treated with immune-based combinations (ARON-1 study)
err2025-11-04
err0
PREAI
errJavier Molina-Cerrillo; Giandomenico Roviello; Maria T. Bourlon; Hana Studentova; Ondrej Fiala; Linda Cerbone; Jakub Kucharz; Jawaher Ansari; Annalisa Zeppellini; Tarek Taha; Sebastiano Buti; Yüksel Ürün; Sarah Scagliarini; Haoran Li; Kaisa Sunela; Se Hoon Park; Mimma Rizzo; Anca Zgura; Rita Chiari; Emmanuel Seront; Martina Catalano; Marwan Ghosn; Alessandra Filosa; Andrey Soares; Francesco Massari; Fernando Sabino Marques Monteiro; Enrique Grande; Camillo Porta; Sergio Bracarda; Matteo Santoni
errShare
errSave
A plain language summary of the TROPiCS-04 study: sacituzumab govitecan use after platinum-based chemotherapy and immunotherapy in people with locally advanced or metastatic cancer of the bladder, urethra, or upper urinary tract
err2025-11-01
err1
PREAI
errPowles, Thomas; Tagawa, Scott T.; Vulsteke, Christof; Gross-Goupil, Marine; Park, Se Hoon; Necchi, Andrea; De Santis, Maria; Duran, Ignacio; Morales-Barrera, Rafael; Guo, Jun; Sternberg, Cora N.; Bellmunt, Joaquim; Goebell, Peter J.; Kovalenko, Maria; Boateng, Freda; Sierecki, Mitch; Wang, Lu; Sima, Camelia S.; Waldes, Jana; Bangs, Rick; Loriot, Yohann; Grivas, Petros
errShare
errSave
Adjuvant nivolumab versus placebo for high-risk muscle-invasive urothelial carcinoma: 5-year efficacy and ctDNA results from CheckMate 274
err2025-10-17
err0
errOAAI
errM.D. Galsky; J.E. Gschwend; M.I. Milowsky; M. Schenker; B.P. Valderrama; Y. Tomita; A. Bamias; T. Lebret; S.F. Shariat; S.H. Park; M. Agerbaek; G. Jha; F. Stenner; D. Ye; F. Giudici; J. Connors; S. Gupta; A. Chhibber; J. Zhang; D.F. Bajorin; J.A. Witjes
errShare
errSave
ctDNA-Guided Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer
err2025-10-01
err10
PREAI
errPowles, Thomas; Kann, Ariel G.; Castellano, Daniel; Gross-Goupil, Marine; Nishiyama, Hiroyuki; Bracarda, Sergio; Bjerggaard Jensen, Jorgen; Makaroff, Lydia; Jiang, Shusuan; Ku, Ja Hyeon; Park, Se Hoon; Reig Torras, Oscar; Ye, Dingwei; Maruzzo, Marco; Necchi, Andrea; Morales-Barrera, Rafael; Giunta, Emilio Francesco; Lee, Jae Lyun; Tortora, Giampaolo; Urun, Yuksel; Dolowy, Lukasz; Erdem, Dilek; Pinto, Alvaro; Grando, Fabricio; Zou, Wei; Assaf, Zoe June; Vuky, Jacqueline; Degaonkar, Viraj; Steinberg, Elizabeth E.; Bellmunt, Joaquim; Gschwend, Jurgen E.
errShare
errSave
Prevalence and clinical implications of PIK3CA aberrations across cancer types: A real-world next-generation sequencing approach
err2025-09-01
err0
PREAI
errKim, Junkyu; Jang, Hye-Lim; Hong, Jung Young; Kim, Seung Tae; Park, Se Hoon; Park, Joon Oh; Kim, Kyoung-Mee; Kim, Deok geun; Lee, Jeeyun; Lim, Sung Hee
errShare
errSave
Angiogenesis gene signatures in patient-derived tumor spheroids for genetic and tumor angiogenesis profiling
err2025-08-07
err0
PREAI
errSujin Hyung ‡; Jihoon Ko ‡; Minae An ‡; Seung Tae Kim; Se Hoon Park; Jung Yong Hong; Sung Hee Lim; Kyoung-Mee Kim; Jeeyun Lee
errShare
errSave
Patient-reported Outcomes in KEYLYNK-010: Pembrolizumab Plus Olaparib Versus Abiraterone or Enzalutamide for Participants with Biomarker-unselected, Previously Treated Metastatic Castration-resistant Prostate Cancer
err2025-07-19
err0
errOAAI
errNiven Mehra; Emmanuel S. Antonarakis; Se Hoon Park; Jeffrey C. Goh; Ray McDermott; Nuria Sala Gonzalez; Peter C. Fong; Richard Greil; Maria De Santis; Patricio Eduardo Yanez; Yi-Hsiu Huang; Stephen D. Begbie; Felipe Rey; Gero Kramer; Hiroyoshi Suzuki; Todd L. Saretsky; Sameer R. Ghate; Yi Cui; Christian Hosius; Evan Y. Yu
errShare
errSave
Avelumab First-line Maintenance for Advanced Urothelial Carcinoma: Long-term Outcomes from the JAVELIN Bladder 100 Trial in Patients with Nonvisceral or Lymph Node–only Disease
err2025-06-03
err0
errOAAI
errJoaquim Bellmunt; Thomas Powles; Se Hoon Park; Eric Voog; Begona P. Valderrama; Howard Gurney; Anders Ullén; Yohann Loriot; Srikala S. Sridhar; Norihiko Tsuchiya; Cora N. Sternberg; Jeanny B. Aragon-Ching; Daniel P. Petrylak; Miguel A. Climent Duran; Karin Tyroller; Jason Hoffman; Natalia Jacob; Petros Grivas; Shilpa Gupta
errShare
errSave
Enfortumab vedotin plus pembrolizumab in untreated locally advanced or metastatic urothelial carcinoma: 2.5-year median follow-up of the phase III EV-302/KEYNOTE-A39 trial☆
err2025-06-01
err0
PREAI
errT.B. Powles; M.S. Van der Heijden; Y. Loriot; J. Bedke; B.P. Valderrama; G. Iyer; E. Kikuchi; J. Hoffman-Censits; C. Vulsteke; A. Drakaki; S. Rausch; W. Arafat; S.H. Park; U. Swami; J.-R. Li; I. Duran; S. Gorla; B. Homet Moreno; X. Yu; Y.-T. Lu; S. Gupta
errShare
errSave
Pembrolizumab plus Lenvatinib in patients with metastatic Renal Cell Carcinoma: real-world evidences from the international ARON-1 study
err2025-05-09
err0
errOAAI
errPorta, Camillo; Massari, Francesco; Taha, Tarek; Grande, Enrique; Bourlon, Maria T.; Kanesvaran, Ravindran; Basso, Umberto; Molina-Cerrillo, Javier; Alonso-Gordoa, Teresa; Myint, Zin W.; Fornarini, Giuseppe; Buttner, Thomas; Park, Se Hoon; Urun, Yueksel; De Giorgi, Ugo; Pichler, Renate; Rescigno, Pasquale; Buchler, Tomas; Studentova, Hana; Melichar, Bohuslav; Ansari, Jawaher; Mollica, Veronica; Kucharz, Jakub; Rizzo, Mimma; Rizzo, Alessandro; Kopp, Ray Manneh; Buti, Sebastiano; Monteiro, Fernando Sabino Marques; Soares, Andrey; Bamias, Aristotelis; Santoni, Matteo
errShare
errSave
Avelumab First-line Maintenance for Advanced Urothelial Carcinoma: Long-term Analyses of Patient-reported Outcomes and Quality-adjusted Time Without Symptoms or Toxicity from the JAVELIN Bladder 100 Trial
err2025-05-02
err0
errOAAI
errPetros Grivas; Jeanny B. Aragon-Ching; Joaquim Bellmunt; Yohann Loriot; Miguel A. Climent Duran; Srikala S. Sridhar; Po-Jung Su; Se Hoon Park; Evgeny Kopyltsov; Yoshiaki Yamamoto; Natalia Jacob; Jason Hoffman; Karin Tyroller; Juliane Manitz; Mairead Kearney; Michael Schlichting; Thomas Powles
errShare
errSave
Paradoxical Effect of Myosteatosis on the Immune Checkpoint Inhibitor Response in Metastatic Renal Cell Carcinoma
err2025-03-07
err0
errOAAI
errYu, Jiwoong; Ahn, Hyeonju; Han, Kyung Yeon; Song, Wan; Sung, Hyun Hwan; Jeon, Hwang Gyun; Jeong, Byong Chang; Seo, Seong Il; Jeon, Seong Soo; Park, Se Hoon; Park, Woong-Yang; Lee, Ji Hyun; Kang, Minyong
errShare
errSave
Concomitant medications in patients with metastatic urothelial carcinoma receiving enfortumab vedotin: real-world data from the ARON-2EV study
err2025-02-20
err0
errOAAI
errFiala, Ondrej; Buti, Sebastiano; Fujita, Kazutoshi; de Liano, Alfonso Gomez; Fukuokaya, Wataru; Kimura, Takahiro; Yanagisawa, Takafumi; Giannatempo, Patrizia; Angel, Martin; Mennitto, Alessia; Molina-Cerrillo, Javier; Bourlon, Maria T.; Soares, Andrey; Takeshita, Hideki; Calabro, Fabio; Ortega, Cinzia; Kucharz, Jakub; Milella, Michele; Seront, Emmanuel; Park, Se Hoon; Tural, Deniz; Benedetti, Giovanni; Urun, Yuksel; Battelli, Nicola; Melichar, Bohuslav; Poprach, Alexandr; Buchler, Tomas; Kopecky, Jindrich; Conteduca, Vincenza; Monteiro, Fernando Sabino Marques; Massari, Francesco; Gupta, Shilpa; Santoni, Matteo
errShare
errSave
Sacituzumab govitecan in advanced urothelial carcinoma: TROPiCS-04, a phase III randomized trial
err2025-02-01
err4
PREAI
errPowles, T.; Tagawa, S.; Vulsteke, C.; Gross-Goupil, M.; Park, S. H.; Necchi, A.; De Santis, M.; Duran, I.; Morales-Barrera, R.; Guo, J.; Sternberg, C. N.; Bellmunt, J.; Goebell, P. J.; Kovalenko, M.; Boateng, F.; Sierecki, M.; Wang, L.; Sima, C. S.; Waldes, J.; Loriot, Y.; Grivas, P.
errShare
errSave
Avelumab maintenance treatment for advanced urothelial cancer: plain language summary of long-term results from the JAVELIN Bladder 100 study
err2025-01-15
err0
errOAAI
errPowles, Thomas; Park, Se Hoon; Gurney, Howard; Loriot, Yohann; Sridhar, Srikala S.; Bellmunt, Joaquim; di Pietro, Alessandra; Grivas, Petros
errShare
errSave
Clinical outcomes by baseline metastases in patients with renal cell carcinoma treated with lenvatinib plus pembrolizumab versus sunitinib: Post hoc analysis of the CLEAR trial
err2024-12-30
err0
errOAAI
errGruenwald, Viktor; Mckay, Rana R.; Buchler, Tomas; Eto, Masatoshi; Park, Se Hoon; Takagi, Toshio; Zanetta, Sylvie; Keizman, Daniel; Suarez, Cristina; Negrier, Sylvie; Lee, Jae Lyun; Santini, Daniele; Bedke, Jens; Staehler, Michael; Kollmannsberger, Christian; Choueiri, Toni K.; Motzer, Robert J.; Burgents, Joseph E.; Xie, Ran; Okpara, Chinyere E.; Powles, Thomas
errShare
errSave
Efficacy and safety of pembrolizumab in patients with advanced urothelial carcinoma deemed potentially ineligible for platinum-containing chemotherapy: Post hoc analysis of KEYNOTE-052 and LEAP-011
errCANCER
IF5.1
err2024-10-28
err0
errOAAI
errO'Donnell, Peter H.; Loriot, Yohann; Csoszi, Tibor; Matsubara, Nobuaki; Shin, Sang Joon; Park, Se Hoon; Atduev, Vagif; Gumus, Mahmut; Karaca, Saziye Burcak; Grivas, Petros; de Wit, Ronald; Castellano, Daniel E.; Powles, Thomas; Vuky, Jacqueline; Zhao, Yujie; O'Hara, Karen; Okpara, Chinyere E.; Franco, Sonia; Moreno, Blanca Homet; Zolnierek, Jakub; Siefker-Radtke, Arlene O.
errShare
errSave
Linkage of alternative exon assembly in Drosophila TrpA1 transcripts
err2024-10-01
err1
errOAAI
errDu, Eun Jo; Lee, MinHyuk; Kim, Seon Yeong; Park, Se Hoon; Ohk, Hye-Jung; Kang, KyeongJin
errShare
errSave